Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281718 · ClinicalTrials.gov registry record · Early Phase 1
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
A Early Phase 1 study, sponsored by Tulane University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT05281718 is a Early Phase 1 study that has completed, run by Tulane University. The registered enrollment target is 12 participants.
The verdict
NCT05281718, a Early Phase 1 study, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study.
Interventions
- DRUG Factor IX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2024-07-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281718
The ClinicalTrials.gov registry entry for NCT05281718 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Factor IX is the first listed.
NCT05281718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05281718 about?
NCT05281718 is a clinical study titled "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)". This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is ...
What is the current status of trial NCT05281718?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2022-08-01. Estimated completion is 2024-07-14.
What interventions are being tested in trial NCT05281718?
The interventions under investigation include: Factor IX (DRUG).
Who is sponsoring clinical trial NCT05281718?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.